Register for free
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bausch Health Companies Inc. Common Stock (TSX:BHC)

9.890 -0.170 (-1.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bausch Health Companies Inc. Common Stock

< Previous 1 2 3 4 5 Next >
New Bausch Health Treatment PrUCERIS(R) (budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults
Via ACCESSWIRE
Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)
Via ACCESSWIRE
Bausch Health's Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA(R)
Via ACCESSWIRE
Bausch Health Announces Second-Quarter 2023 Results, Other Key Updates From the Quarter, and Raises Full-Year 2023 Revenue Outlook
Via ACCESSWIRE
Ortho Dermatologics Announces 2023 Aspire Higher Scholarship Recipients
Via ACCESSWIRE
Salix Announces 2023 Gastrointestinal Health Scholars Program Winners
Via ACCESSWIRE
Salix to Present Data from XIFAXAN(R) (Rifaximin) Clinical Research at EASL's International Liver Congress(TM) 2023
Via ACCESSWIRE
Bausch Health to Announce Second-Quarter 2023 Results on Aug. 3
Via ACCESSWIRE
OraPharma to Participate in the First-Ever Research and Technology Pavilion Sponsored by Pacific Dental Services(R) at the American Dental Hygienists' Association (ADHA(R)) Annual Conference
Via ACCESSWIRE
Bausch Health Enters Into $600 Million Financing Facility With KKR
Via ACCESSWIRE
Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA(R)
Via ACCESSWIRE
Bausch Health Responds to Norwich's ANDA Tentative Approval and Lawsuit Against United States Food and Drug Administration
Via ACCESSWIRE
Bausch Health Announces 2023 Annual Meeting of Shareholder Results
Via ACCESSWIRE
Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023
Via ACCESSWIRE
Bausch Health Announces First-Quarter 2023 Results
Via ACCESSWIRE
New Clinical Study Suggests the Use of OraPharma’s ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with Periodontitis
Via ACCESSWIRE
U.S. District Court Upholds Final Judgment for XIFAXAN(R) 550 mg That Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029
Via ACCESSWIRE
Bausch Health Observes Mental Health Awareness Month
Via ACCESSWIRE
New Artificial Intelligence Tool Can Diagnose Colon Cancer
A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and... 
Via PressReach
Topics Artificial Intelligence Death
Ortho Dermatologics Announces U.S. Food and Drug Administration New Drug Application Filing Acceptance for Investigational Acne Treatment IDP-126 Gel
Via ACCESSWIRE
Salix Partners with the Colorectal Cancer Alliance on Community Screening Program
Via ACCESSWIRE
Bausch Health to Announce First-Quarter 2023 Results on May 4
Via ACCESSWIRE
New Research: More Than Half of IBS Patients Surveyed Report Waiting More Than One Year Before Discussing IBS Symptoms With Their Healthcare Provider
Via ACCESSWIRE
Bausch Health Announces Changes to its Board of Directors
Via ACCESSWIRE
Bausch Health Announces Fourth-Quarter and Full-Year 2022 Results
Via ACCESSWIRE
Salix Announces 2023 Gastrointestinal Health Scholars Program
Via ACCESSWIRE
Bausch Health to Announce Fourth-Quarter and Full-Year 2022 Results on Feb. 23
Via ACCESSWIRE
Bausch Health Wins DUOBRII(R) and BRYHALI(R) Patent Infringement Case
Via ACCESSWIRE
Salix Pharmaceuticals Culminates Year-Long Constipation Awareness Campaign with New Social Media and Digital Initiatives Empowering Patients to Discuss Their Symptoms with a Health Care Provider
Via ACCESSWIRE
Struggling Axsome Stock Could Bounce Back on Drug Trial Success
Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that. 
Via MarketBeat
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS